Literature DB >> 25064116

Generating double knockout mice to model genetic intervention for diabetic cardiomyopathy in humans.

Vishalakshi Chavali1, Shyam Sundar Nandi, Shree Ram Singh, Paras Kumar Mishra.   

Abstract

Diabetes is a rapidly increasing disease that enhances the chances of heart failure twofold to fourfold (as compared to age and sex matched nondiabetics) and becomes a leading cause of morbidity and mortality. There are two broad classifications of diabetes: type1 diabetes (T1D) and type2 diabetes (T2D). Several mice models mimic both T1D and T2D in humans. However, the genetic intervention to ameliorate diabetic cardiomyopathy in these mice often requires creating double knockout (DKO). In order to assess the therapeutic potential of a gene, that specific gene is either overexpressed (transgenic expression) or abrogated (knockout) in the diabetic mice. If the genetic mice model for diabetes is used, it is necessary to create DKO with transgenic/knockout of the target gene to investigate the specific role of that gene in pathological cardiac remodeling in diabetics. One of the important genes involved in extracellular matrix (ECM) remodeling in diabetes is matrix metalloproteinase-9 (Mmp9). Mmp9 is a collagenase that remains latent in healthy hearts but induced in diabetic hearts. Activated Mmp9 degrades extracellular matrix (ECM) and increases matrix turnover causing cardiac fibrosis that leads to heart failure. Insulin2 mutant (Ins2+/-) Akita is a genetic model for T1D that becomes diabetic spontaneously at the age of 3-4 weeks and show robust hyperglycemia at the age of 10-12 weeks. It is a chronic model of T1D. In Ins2+/- Akita, Mmp9 is induced. To investigate the specific role of Mmp9 in diabetic hearts, it is necessary to create diabetic mice where Mmp9 gene is deleted. Here, we describe the method to generate Ins2+/-/Mmp9-/- (DKO) mice to determine whether the abrogation of Mmp9 ameliorates diabetic cardiomyopathy.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25064116      PMCID: PMC7218297          DOI: 10.1007/978-1-4939-1215-5_22

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  32 in total

Review 1.  Matrix metalloproteinases: regulation and dysregulation in the failing heart.

Authors:  Francis G Spinale
Journal:  Circ Res       Date:  2002-03-22       Impact factor: 17.367

2.  Myocardial protection from ischemia/reperfusion injury by targeted deletion of matrix metalloproteinase-9.

Authors:  Anne M Romanic; Stephen M Harrison; Weike Bao; Cynthia L Burns-Kurtis; Susan Pickering; Juanli Gu; Evelyn Grau; Joyce Mao; Ganesh M Sathe; Eliot H Ohlstein; Tian Li Yue
Journal:  Cardiovasc Res       Date:  2002-06       Impact factor: 10.787

3.  Ablation of MMP9 induces survival and differentiation of cardiac stem cells into cardiomyocytes in the heart of diabetics: a role of extracellular matrix.

Authors:  Paras Kumar Mishra; Vishalakshi Chavali; Naira Metreveli; Suresh C Tyagi
Journal:  Can J Physiol Pharmacol       Date:  2012-03-06       Impact factor: 2.273

4.  MicroRNAs are involved in homocysteine-induced cardiac remodeling.

Authors:  Paras K Mishra; Neetu Tyagi; Soumi Kundu; Suresh C Tyagi
Journal:  Cell Biochem Biophys       Date:  2009-08-11       Impact factor: 2.194

5.  A cross-national comparative study of metabolic syndrome among non-diabetic Dutch and English ethnic groups.

Authors:  Charles Agyemang; Anton E Kunst; Raj Bhopal; Paola Zaninotto; James Nazroo; Nigel Unwin; Irene van Valkengoed; William K Redekop; Karien Stronks
Journal:  Eur J Public Health       Date:  2012-04-28       Impact factor: 3.367

6.  Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections.

Authors:  H King; R E Aubert; W H Herman
Journal:  Diabetes Care       Date:  1998-09       Impact factor: 19.112

7.  Diabetes patients requiring glucose-lowering therapy and nondiabetics with a prior myocardial infarction carry the same cardiovascular risk: a population study of 3.3 million people.

Authors:  Tina Ken Schramm; Gunnar H Gislason; Lars Køber; Søren Rasmussen; Jeppe N Rasmussen; Steen Z Abildstrøm; Morten Lock Hansen; Fredrik Folke; Pernille Buch; Mette Madsen; Allan Vaag; Christian Torp-Pedersen
Journal:  Circulation       Date:  2008-03-31       Impact factor: 29.690

8.  Changes in racial/ethnic disparities in the prevalence of Type 2 diabetes by obesity level among US adults.

Authors:  Qi Zhang; Youfa Wang; Elbert S Huang
Journal:  Ethn Health       Date:  2009-10       Impact factor: 2.772

Review 9.  MicroRNAs as a therapeutic target for cardiovascular diseases.

Authors:  Paras Kumar Mishra; Neetu Tyagi; Munish Kumar; Suresh C Tyagi
Journal:  J Cell Mol Med       Date:  2009-03-13       Impact factor: 5.310

Review 10.  Stem cells as a therapeutic target for diabetes.

Authors:  Paras Kumar Mishra; Shree Ram Singh; Irving G Joshua; Suresh C Tyagi
Journal:  Front Biosci (Landmark Ed)       Date:  2010-01-01
View more
  5 in total

1.  MMP9 inhibition increases autophagic flux in chronic heart failure.

Authors:  Shyam S Nandi; Kenichi Katsurada; Neeru M Sharma; Daniel R Anderson; Sushil K Mahata; Kaushik P Patel
Journal:  Am J Physiol Heart Circ Physiol       Date:  2020-10-16       Impact factor: 4.733

2.  Interleukin 17A deficiency alleviates neuroinflammation and cognitive impairment in an experimental model of diabetic encephalopathy.

Authors:  Xiao-Xia Fang; Fen-Fen Xu; Zhan Liu; Bei-Bei Cao; Yi-Hua Qiu; Yu-Ping Peng
Journal:  Neural Regen Res       Date:  2022-12       Impact factor: 6.058

3.  IL-17A is involved in diabetic inflammatory pathogenesis by its receptor IL-17RA.

Authors:  Ao-Wang Qiu; Xin Cao; Wei-Wei Zhang; Qing-Huai Liu
Journal:  Exp Biol Med (Maywood)       Date:  2020-09-09

4.  Ablation of Matrix Metalloproteinase-9 Prevents Cardiomyocytes Contractile Dysfunction in Diabetics.

Authors:  Priyanka Prathipati; Naira Metreveli; Shyam Sundar Nandi; Suresh C Tyagi; Paras K Mishra
Journal:  Front Physiol       Date:  2016-03-15       Impact factor: 4.566

5.  Ginsenoside Rh2 Improves Cardiac Fibrosis via PPARδ-STAT3 Signaling in Type 1-Like Diabetic Rats.

Authors:  Shih-Hsiang Lo; Chao-Tien Hsu; Ho-Shan Niu; Chiang-Shan Niu; Juei-Tang Cheng; Zhih-Cherng Chen
Journal:  Int J Mol Sci       Date:  2017-06-26       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.